 Relief Therapeutics is in advanced clinical trials with their drug RLF-100 which aims to halt COVID-19 and reverse its devastating effects; Just-released Compassionate Use results showed stunning results: ventilator-dependent Covid-19 patients with deadly co-morbidities coming off the ventilator and returning home in only five days after treatment with RLF-100; Relief Therapeutics RLF-100 is both easy to manufacture at scale and inexpensive, meaning that success in clinical trials could translate to rapid worldwide production and availability; If in-progress clinical trials reflect the Compassionate Use results, RLF-100 will likely garner immediate approval and shares could go much higher. 